Greg Jefferys Hepatitis C blog deals with all the issues associated with hepatitis C
There is a mounting body of scientific evidence that the Hepatitis C drug combination of Sofosbuvir + Daclatasvir is effective for significantly reducing death rates amongst people with COVID 19 and is probably an effective cure for COVID 19.
I have delayed writing this article for quite a few weeks now because there have been so many “nutters” writing crazy stuff about COVID 19. Because of this, I did not want to contribute to overall confusion about the coronavirus pandemic and possible treatments for COVID 19.
But I cannot put off writing any longer about this apparent cure for COVID 19 because I see so many people suffering because of the same combination of greed, stupidity, and corruption that has been the cause of so much suffering for people infected with Hepatitis C.
Access to affordable health care and the treatment of diseases should be a basic human right. In the case of Hepatitis C and COVID 19 Big Pharma’s quest for massive profits has corrupted the global health systems. In the case of Hepatitis C treatment is inaccessible to millions of people because of the predatory pricing policies of Big Pharma. In the case of COVID 19 Big Pharma has used its power to influence and manipulate the discussion and research into COIVD 19 treatment. The confusion and misinformation around the use of Hydroxychloroquine is just one example of this.
The astounding lack of interest by government and medical institutions in the very real possibility that Sofosbuvir + Daclatasvir, the world’s most effective direct-acting antiviral combination, is yet another example of Big Pharma’s ability to manipulate and control pharmaceutical and medical research.
It would appear that there are at least two effective treatments, or cures, for COVID 19 that are being ignored by governments and medical science simply because Big Pharma wants them to be ignored.
In particular, Big Pharma does not want anyone to discover a previously used drug that is cheap that can cure COVID 19 and has been proved to be harmless to humans.
What Big Pharma wants is to patent either a drug that cures COVID 19 or a reasonably effective vaccine that prevents COVID 19.
Big Pharma would probably prefer a vaccine because that would mean billions of sales every year for decades, whereas a medicinal cure would only get used on those people who actually have symptoms from COVID 19, which would probably be less than 50 million sales per year.
The BIG money is in the COVID 19 vaccine, the second prize would be a patented pharmaceutical cure for COVID 19.
Since the advent of the COVID 19 pandemic, there have been a small number of laboratory-based trials investigating the use of Sofosbuvir and Daclatasvir to “kill” COVID 19.
The earliest of these was in January 2020 and since then there have been a number of in silico and in vitro trials indicating Sofosbuvir and/or Daclatasvir stop COVID 19 viruses from replicating in human cells, just as they do with Hepatitis C viruses.
These trials have all shown that these two drugs have fantastic potential as a treatment for COVID 19.
Despite these very encouraging results no governments or drug companies would fund human trials of Sofosbuvir + Daclatasvir as a treatment for COVID 19.
Even though we know that Sofosbuvir and Daclatasvir have almost no toxicity problems for humans and that a two-week treatment would cost less than US$100.
The current indications are that a person diagnosed with COIVD 19 be treated with a daily dose of Sofosbuvir 400 mg + Daclatasvir 60 mg for 14 days.
At current retail prices, this treatment would cost about US$75 for 14 days. If governments made bulk purchases of Sofosbuvir + Daclatasvir, let’s say 10,000 treatments, the cost per treatment would drop to less than US$20 per treatment.
Compare the price of a treatment with Sof +Daclatasvir to GILEAD’s remdesivir which costs the US government over US$3,100 per treatment and appears to be LESS effective than Sofosbuvir + Daclatasvir!
Yes, even though the US government is buying every bit of remdesivir that Gilead produces it is paying more than 100 times what Sofosbuvir + Daclatasvir would cost… and Sofosbuvir + Daclatasvir probably does a better job!
Whilst governments and Big Pharma have been throwing billions and billions of dollars at vaccine research it has been almost impossible for scientists interested in investigating Sofosbuvir + Daclatasvir to get funding for research on Sofosbuvir + Daclatasvir as a possible effective treatment for COVID 19.
But there are some determined people and activist groups who have pushed this research forward on a shoestring budget and have begun trials using Sofosbuvir + Daclatasvir on people infected with COVID 19.
I have been fortunate enough to be allowed to observe several of these trials from their early stages and been privy to early results.
Now I would like to share the results of the first of these trials on the treatment of COVID 19 with Sof + Dac to be published in a peer-reviewed scientific journal.
Below is a summary of the results and also a link to the complete journal article.
As you will see, it would appear that Sofosbuvir + Daclatasvir is more effective than any existing treatment for COVID 19.
Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19.
Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT–PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir. All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine. The primary endpoint was time from starting the medication until discharge from hospital with secondary endpoints of duration of ICU stay and mortality.
Sixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm. The median duration of stay was 5 days for the sofosbuvir/daclatasvir group and 9 days for the ribavirin group. The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group. The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 (95% CI 0.04–0.73, P = 0.02) and the number needed to treat for benefit was 3.6 (95% CI 2.1–12.1, P < 0.01).
Given these encouraging initial results, and the current lack of treatments proven to decrease mortality in COVID-19, further investigation in larger-scale trials seems warranted.
|Outcome||SOF/DCV (n = 35)||RBV (n = 27)||P value|
|Duration of hospital stay, median days (IQR)||5 (5–7)||9 (6–11)||<0.01|
|Recovered, n (%)||33 (94%)||18 (67%)||0.01|
|time to recovery, median (IQR)||6 (5–8)||11 (9–?a)||<0.01|
|Admitted to ICU, n (%)||6 (17%)||13 (48%)||0.01|
|days in ICU, median (IQR)||3.5 (2–4)||5 (2–10)||0.24|
|days in ICU, mean (SD)||3.5 (2.1)||5.6 (4.0)||0.24|
|relative risk of ICU admission (95% CI)||0.36 (0.16–0.81)||2.8 (1.2–6.4)||0.01|
|Deaths, n (%)||2 (5.7%)||9 (33%)||0.01|
|relative risk of death (95% CI)||0.17 (0.04–0.73)||5.8 (1.4–25)||0.02|
SOF/DCV, sofosbuvir/daclatasvir; RBV, ribavirin.
Sofosbuvir/daclatasvir Covid 19
Covid 19 Protocol Of Treatment, Covid 19 Treatment And Vaccine News, Covid 19 Treatment Latest, Covid 19 Treatment News, Covid 19 Treatment News Today, Covid 19 Treatments That Are Working, Covid-19 Treatment Update Today, Current Covid 19 Treatment Trials